# Nucelion to manufacture VeGen Bio's clinical-stage cell therapy in India

_Published Wednesday, October 21, 2026 at 9:19 AM EDT · Science · Latest · Tier 2 — Notable_

![Nucelion to manufacture VeGen Bio's clinical-stage cell therapy in India — Primary](https://cdn.expresspharma.in/wp-content/uploads/2021/05/04131504/handshake.jpg)

Nucelion Therapeutics and VeGen Bio announced a collaboration to transfer and manufacture VL-2511, VeGen's Phase II cell therapy candidate for multiple myeloma, in India. Nucelion, a Bharat Biotech subsidiary, will provide technology transfer and clinical- and commercial-stage manufacturing at its single-site facility.

VL-2511 uses a patient's own modified immune cells to target BCMA and CD19 simultaneously, aiming to address cancer cells escaping recognition by losing a target. The partnership covers process development and manufacturing scale-up rather than marketing or distribution. The companies aim to improve yields and reduce manufacturing costs.

## Sources

- [Express Pharma](https://www.expresspharma.in/nucelion-therapeutics-vegen-bio-collaborate-on-car-t-cell-therapy-manufacturing/)

---
Canonical: https://techandbusiness.org/newswire/3eTv20ZAPZRpAB7wAq6b7O
Published: 2026-10-21T13:19:35.017Z
Story chronology: 2026-10-21T10:48:02.000Z
Retrieved: 2026-10-25T06:19:18.703Z
Publisher: Tech & Business (techandbusiness.org)